Articles

Health Inequity in People with Cystic Fibrosis: Can We Close the Gap? Annals of the American Thoracic Society

Global prevalence of CFTR variants with respect to their responsiveness to elexacaftor-tezacaftor-ivacaftor. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society

Factors associated with sustained Pseudomonas aeruginosa infection following elexacaftor/tezacaftor/ivacaftor treatment: Real-world data from the European cystic fibrosis society patient registry.

Respiratory infections after elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis: analysis of the European Cystic Fibrosis Society Patient Registry.

Methicillin-Resistant Staphylococcus Aureus and Pulmonary Outcome in People with Cystic Fibrosis: A European Cystic Fibrosis Patient Registry Data Analysis.

Variability in disease severity among cystic fibrosis patients carrying residual-function variants: data from the European Cystic Fibrosis Society Patient Registry.

Impact of COVID-19 infection on lung function and nutritional status amongst individuals with cystic fibrosis: A global cohort study.

Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study.

Cystic fibrosis in Europe: improved lung function and longevity - reasons for cautious optimism, but challenges remain.

A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA.

Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children.

Association of Oxygen Therapy with the Natural Disease Progression of Cystic Fibrosis: A Multi-State Model of the European Cystic Fibrosis Society Patient Registry.

Collaborative Group. Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis: data from the European Cystic Fibrosis Society Patient Registry.

Clinical outcomes associated with Achromobacter species infection in people with cystic fibrosis.

Prevalence, trends and outcomes of long-term inhaled antibiotic treatment in people with cystic fibrosis without chronic Pseudomonas aeruginosa infection - A European cystic fibrosis patient registry data analysis.

Disease severity of people with cystic fibrosis carrying residual function mutations: Data from the ECFS Patient Registry.

Heterozygous People With Cystic Fibrosis Harboring One F508del CFTR Gene Mutation.

Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation.

Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe.

European Cystic Fibrosis COVID project group. Incidence of SARS-CoV-2 in people with cystic fibrosis in Europe between February and June 2020.

Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.

Dornase alfa and rate of lung function decline in European patients with cystic fibrosis: A retrospective registry cohort study.

Gene in Homozygous State Causes Mild Cystic Fibrosis – Overview of Longitudinal Clinical Data of the Patient Managed in our CF Center and Review of the Literature.

Cystic fibrosis related diabetes in Europe: Prevalence, risk factors and outcome; Olesen et al.

Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry.

Characteristics of cystic fibrosis-related diabetes: Data from two different sources the European cystic fibrosis society patient registry and German/Austrian diabetes prospective follow-up registry.

Data from European Cystic Fibrosis Society Patient Registry.

Creating longitudinal datasets and cleaning existing data identifiers in a cystic fibrosis registry using a novel Bayesian probabilistic approach from astronomy.

Effect of allergic bronchopulmonary aspergillosis on FEV1 in children and adolescents with cystic fibrosis: a European Cystic Fibrosis Society Patient Registry analysis.

Year to year change in FEV1 in patients with cystic fibrosis and different mutation classes.

Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF).

International prospective study of distal intestinal obstruction syndrome in cystic fibrosis: Associated factors and outcome.

Future trends in cystic fibrosis demography in 34 European countries.

The relative frequency of CFTR mutation classes in European patients with cystic fibrosis.

Multi-country estimate of different manifestations of aspergillosis in cystic fibrosis.

The European Cystic Fibrosis Society Patient Registry: valuable lessons learned on how to sustain a disease registry.

Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.

Evidence of diminished FEV1 and FVC in 6-year-olds followed in the European Cystic Fibrosis Patient Registry, 2007-2009.

A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect.

Reference percentiles for FEV(1) and BMI in European children and adults with cystic fibrosis.

Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries.

Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis.